News
Design 5 provides information on treatment effects, individual-to-individual variability, and probe/chip-to-probe/chip variability. The strength and weakness of each design will be discussed.
Affymetrix plans the limited release of a new set of gene chips that will each carry 6.5 million varieties of DNA probes. The company has also been stuffing more information onto every chip.
Here we use a comprehensive study design to generate Illumina RNA-seq and Affymetrix microarray ... the Affymetrix GeneChip array probe sets were collapsed into 27,146 UniGene transcript ...
Santa Clara, Calif.-based Affymetrix's new GeneChip® Human Genome U133 set is the first commercially available microarray set designed using the April 2001 draft of the human genome. Affymetrix ...
Affymetrix Releases Data from Validated SNP Database for Designing Custom Genotyping Arrays- Validated SNPs from 1000 Genomes Project and custom Axio ...
Genomatix Software GmbH today announced that it has achieved GeneChip-compatibleTM status for several products with the Affymetrix Inc. (Nasdaq: AFFX) GeneChip® microarray platform and that it ...
Photo: Courtesy of Affymetrix Affymatrix Hybridization Pattern, the human p53 Gene Affymetrix, the Santa Clara-based DNA chip company, has partnered with Hewlett Packard in the development of the HP ...
Molecular Profiling Institute secures $7.5 million in Series B funding AmeriPath, Affymetrix, and Gen-Probe provide funding to accelerate the introduction of new genetic-based prognostics to ...
Affymetrix’ QuantiGene ViewRNA assay will be available in Q3 2012 on the Leica BOND RX platform.
For Affymetrix probe sets, intratumor variance is generally a small component of total variance. Histograms stratified by (A) expression level demonstrate that profiles differ sharply between highly ...
Affymetrix, Inc. has announced that it has released a data set based on extensive validation of novel SNPs from the 1000 Genomes Project. This data will give researchers access to more rare mutations ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results